International Journal of Radiation Oncology * Biology * Physics
Volume 49, Issue 4 , Pages 937-946 , 15 March 2001

Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate

  • Colleen A Lawton, M.D. (F.A.C.R.)

      Affiliations

    • Medical College of Wisconsin, Radiation Oncology, Milwaukee, WI, USA
    • Corresponding Author InformationReprint requests to: Dr. Colleen A. Lawton, Medical College of Wisconsin, Department of Radiation Oncology, 8701 Watertown Plank Road, Milwaukee WI 53226
    • ,
  • Kathryn Winter, M.S.

      Affiliations

    • RTOG, Statistical Unit, Philadelphia, PA, USA
    • ,
  • Kevin Murray, M.D.

      Affiliations

    • Medical College of Wisconsin, Radiation Oncology, Milwaukee, WI, USA
    • ,
  • Mitchell Machtay, M.D.

      Affiliations

    • University of Pennsylvania, Philadelphia, PA, USA
    • ,
  • John B Mesic, M.D.

      Affiliations

    • Radiation Oncology Center, Sacramento, CA, USA
    • ,
  • Gerald E Hanks, M.D. (F.A.C.R.)

      Affiliations

    • Fox Chase Cancer Center, Philadelphia, PA, USA
    • ,
  • Christopher T Coughlin, M.D. (F.A.C.R.)

      Affiliations

    • Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA
    • ,
  • Miljenko V Pilepich, M.D.

      Affiliations

    • St. Joseph Mercy Hospital, Ann Arbor, MI, USA

,Accepted 4 October 2000.

References 

  1. Huggins C, Hodges CV. Studies on prostatic cancer I. The effects of castration of estrogen and of androgen injection on semina phosphates in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293–397
  2. Green N, Bodner H, Broth H, et al.  Improved local control of bulky prostatic carcinoma with sequential estrogen and radiation therapy. Int J Radiat Oncol Biol Phys. 1984;10:971–976
  3. Porter AT, Venner PM: The role of cytoreduction prior to definitive radiotherapy in locally advanced prostate cancer—The Canadian perspective. Treatment of prostatic cancer—Facts and controversies. New York: Wiley-Liss, Inc; 1990. p. 231–237.
  4. Kramlowsky: Value of testosterone deprivation in D1 carcinoma of the prostate. J Urol 1998;139:1242–1244.
  5. Pilepich MV, Krall JM, John MJ, et al.  Hormonal cytoreduction in locally advanced carcinoma of the prostate treated with definitive radiotherapy. Primary results of RTOG 83-07. Int J Radiat Oncol Biol Phys. 1989;16:813–817
  6. Pilepich MV, Caplan R, Byhardt RW, et al.  Phase III trial of androgen suppression using Goserelin in unfavorable-prognostic carcinoma of the prostate treated with definitive radiotherapy (Report of RTOG 85-31). J Clin Oncol. 1997;15:3;1013–3;1021
  7. Pilepich MV, Winter K, Roach M, et al.  Phase III RTOG Trial 86-10 of androgen deprivation before and during radiotherapy in locally advanced carcinoma of the prostate. Proc ASCO. 1998;17:308a;(Abstr.)
  8. Bolla M, Gonzalez D, Warde P, et al.  Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and Goserelin. N Eng J Med. 1997;337(5):295–300
  9. Zelen M. The randomization and stratification of patients to clinical trials. J Chron Dis. 1974;27:365–375
  10. Kalbfleish JD, Prentice RL. In: The statistical analysis of failure time data. New York: John Wiley & Sons; 1980;p. 167–169
  11. Gray RJ. A class of K-sample tests comparing the cumulative incidence of a competing risk. J Ann Stat. 1988;16:1141–1154
  12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Ann Stat Assoc. 1958;53:457–481
  13. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;5:163–170
  14. Cox DR. Regression models and life tables. J R Stat Soc B. 1972;34:187–229

PII: S0360-3016(00)01516-9

doi: 10.1016/S0360-3016(00)01516-9

International Journal of Radiation Oncology * Biology * Physics
Volume 49, Issue 4 , Pages 937-946 , 15 March 2001

Article Tools

* Image Usage & Resolution